Stringer KA - Search Results

1

Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.

Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM; ESSENCE and TIMI 11B Investigators. Spinler SA, et al. Among authors: stringer ka. Am Heart J. 2003 Jul;146(1):33-41. doi: 10.1016/S0002-8703(03)00121-2. Am Heart J. 2003. PMID: 12851605

2

Thrombolytic therapy for acute myocardial infarction.

Meister FL, Stringer KA, Spinler SA, Gonzalez E, Talbert RL, Weiner B, Guerrero RM, Smith R. Meister FL, et al. Among authors: stringer ka. Pharmacotherapy. 1998 Jul-Aug;18(4):686-98. Pharmacotherapy. 1998. PMID: 9692643 Review.

3

TIMI grade flow, mortality, and the GUSTO-III trial.

Stringer KA. Stringer KA. Pharmacotherapy. 1998 Jul-Aug;18(4):699-705. Pharmacotherapy. 1998. PMID: 9692644 Review.

4

Bivalirudin: a direct thrombin inhibitor for percutaneous transluminal coronary angioplasty.

Wiggins BS, Spinler S, Wittkowsky AK, Stringer KA. Wiggins BS, et al. Among authors: stringer ka. Pharmacotherapy. 2002 Aug;22(8):1007-18. doi: 10.1592/phco.22.12.1007.33600. Pharmacotherapy. 2002. PMID: 12173785 Review.

5

Discrepancies in identification of bleeding events after percutaneous coronary intervention.

McCollum M, Stringer KA, Wittkowsky AK, Young S, Spinler SA. McCollum M, et al. Among authors: stringer ka. Pharmacotherapy. 2007 Jan;27(1):36-40. doi: 10.1592/phco.27.1.36. Pharmacotherapy. 2007. PMID: 17192160

6

Clinical trials in thrombolytic therapy, Part 1: Outcome markers that go beyond mortality reduction.

Stringer KA. Stringer KA. Am J Health Syst Pharm. 1997 Nov 15;54 Suppl 1:S23-6. doi: 10.1093/ajhp/54.suppl_1.S23. Am J Health Syst Pharm. 1997. PMID: 9397234 Review.

7

An institution-specific heparin titration nomogram: development, validation, and assessment of compliance.

Sherman DS, Clarke SH, Lefkowitz JB, Valuck RJ, Lindenfeld J, Stringer KA. Sherman DS, et al. Among authors: stringer ka. Pharmacotherapy. 2001 Oct;21(10):1167-74. doi: 10.1592/phco.21.15.1167.33895. Pharmacotherapy. 2001. PMID: 11601661 Clinical Trial.

8

The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes.

Stringer KA. Stringer KA. Ann Pharmacother. 1999 Jun;33(6):712-22. doi: 10.1345/aph.18327. Ann Pharmacother. 1999. PMID: 10410186 Review.

9

Emergence of low-molecular-weight heparins in cardiology.

Stringer KA. Stringer KA. Pharmacotherapy. 1999 Sep;19(9 Pt 2):141S-146S. doi: 10.1592/phco.19.14.141s.31706. Pharmacotherapy. 1999. PMID: 10610004 Review.

10

Impact of a critical pathway on acute myocardial infarction quality indicators.

Bestul MB, McCollum M, Stringer KA, Burchenal J. Bestul MB, et al. Among authors: stringer ka. Pharmacotherapy. 2004 Feb;24(2):173-8. doi: 10.1592/phco.24.2.173.33139. Pharmacotherapy. 2004. PMID: 14998217

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

138 results

Search Page

Filters